Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 18 of 116

  1. Nimotuzumab

    Praxis Precision Medicines

    Pancreatic Cancer, Advanced or Metastatic

    phase 3 small molecule completed

    1 trial

  2. Nimotuzumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  3. Niraparib

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  4. Niraparib Placebo Tablets

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  5. Niraparib tosylate monohydrate + abiraterone... for Prostate Cancer

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  6. Nivolumab

    Bristol-Myers Squibb

    Brain Neoplasms

    phase 3 small molecule completed

    1 trial

  7. Nivolumab

    Bristol-Myers Squibb

    Bladder Cancer

    phase 3 mab completed

    1 trial

  8. Nivolumab

    Bristol-Myers Squibb

    Colorectal Cancer

    phase 3 mab completed

    1 trial

  9. Nivolumab

    Ono Pharmaceutical Co.,

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  10. Nivolumab

    Bristol-Myers Squibb

    Head and Neck Cancer

    phase 3 mab completed

    1 trial

  11. Nivolumab

    Bristol-Myers Squibb

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  12. Nivolumab

    Shanghai Reinovax Biologics Co.,LTD

    Metastatic Kidney Cancer

    phase 3 small molecule active

    1 trial

  13. Nivolumab

    Nektar Therapeutics UK Limited

    Bladder Cancer

    phase 3 mab completed

    1 trial

  14. OBI-822-011

    Lacuna Pharma Pty Ltd

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  15. OLAPARIB

    AstraZeneca

    Platinum Sensitive Relapsed Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  16. ONO-4059-17

    Lacuna Pharma Pty Ltd

    Relapsed/refractory primary central nervous system lymphoma

    phase 3 small molecule active

    1 trial

  17. OP-1250-301

    Olema Pharmaceuticals

    ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy

    phase 3 small molecule active

    1 trial

  18. OP-1250-302

    Olema Pharmaceuticals

    ER+, HER2- Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  19. OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    oesophageal cancer

    phase 3 small molecule active

    1 trial

  20. OT-101

    Oncotelic Therapeutics

    Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  21. Obatoclax Mesylate, Carboplatine and Etoposide

    Teva Pharma GmbH

    Extensive-stage Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  22. Obinutuzumab

    United Therapeutics Europe Ltd

    Non-Hodgkin's Lymphoma

    phase 3 small molecule completed

    1 trial

  23. Obinutuzumab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 mab terminated

    1 trial

  24. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma (FL)

    phase 3 small molecule active

    2 trials

  25. Odronextamab

    Regeneron UK Limited

    Diffuse Large B-cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  26. Odronextamab

    Regeneron UK Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  27. Odronextamab

    ADC Therapeutics SA

    B-cell Non Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  28. Olaparib

    AstraZeneca

    Breast Cancer Metastatic

    phase 3 small molecule completed

    1 trial

  29. Olaparib 300mg tablets

    AstraZeneca

    Relapsed Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  30. Oral immunonutrition

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 3 other active

    1 trial

  31. Orteronel

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    3 trials

  32. Osimertinib

    The First People's Hospital of Lianyungang

    Non-small Cell Carcinoma

    phase 3 small molecule active

    1 trial

  33. Osimertinib

    AstraZeneca

    Cancer

    phase 3 small molecule active

    1 trial

  34. Oxaliplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  35. Oxaliplatin

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  36. Oxybutynin Chloride

    United Therapeutics Europe Ltd

    Breast Carcinoma

    phase 3 small molecule completed

    1 trial

  37. P.64Cu.003.01

    A.C.O.M. - Advanced Center Oncology

    Prostate cancer at risk of developing metastatic lesions

    phase 3 small molecule active

    1 trial

  38. PACIFIC2/D933KC00001

    AstraZeneca AB

    Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)

    phase 3 small molecule active

    1 trial

  39. PBP-301

    Lacuna Pharma Pty Ltd

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  40. PD-0332991

    Pfizer

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  41. PEAK-1

    Arcus Biosciences

    Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  42. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Squamous cell carcinoma of head and neck

    phase 3 small molecule active

    1 trial

  43. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.

    phase 3 small molecule active

    1 trial

  44. PEMBROLIZUMAB , BNT113

    BioNTech SE

    Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer

    phase 3 small molecule active

    1 trial

  45. PF-02341066

    Pfizer

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    2 trials

  46. PF-05280014

    Pfizer

    Metastatic Breast Cancer

    phase 3 mab completed

    1 trial

  47. PF-05280586

    Pfizer

    Follicular Lymphoma

    phase 3 mab completed

    1 trial

  48. PF-06801591

    Pfizer

    Non-muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.